TNFRSF8 and Hodgkins lymphoma: Brentuximab Vedotin (Bv), is a targeted monoclonal antibody-drug conjugate (ADC) active against CD30-positive cancer cells, such as those associated with classical Hodgkin lymphoma or Anaplastic large cell lymphomas (ALCL) (7, 8).